Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Calidi Biotherapeutics Inc CLDI

Alternate Symbol(s):  CLDWW

Healthcare Biotechnology
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf... see more

Recent & Breaking News (NYSEAM:CLDI)

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

Business Wire June 3, 2024

 Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Business Wire May 31, 2024

ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire May 24, 2024

Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV

Accesswire May 17, 2024

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

Business Wire May 14, 2024

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Business Wire May 1, 2024

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24

Business Wire April 23, 2024

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

Business Wire April 19, 2024

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

Business Wire April 16, 2024

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024

Business Wire April 9, 2024

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

Business Wire March 15, 2024

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

Business Wire March 11, 2024

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

Business Wire February 12, 2024

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Business Wire January 8, 2024

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Business Wire December 13, 2023

Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors

Business Wire December 12, 2023

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones

Business Wire November 20, 2023

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results

Business Wire November 14, 2023

Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023)

Business Wire November 3, 2023

Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment

Business Wire November 1, 2023